Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Depression, Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | November 2015 |
A Randomized Double-Blind Placebo-Controlled Pilot Study of L-tyrosine and L-tryptophan in Depressed Patients Receiving L-methylfolate and and SSRI
The purpose of this study is to determine if adding over the counter nutritional supplements
will have a benefit to participants currently taking prescribed antidepressants who have not
experienced complete remission of their depression symptoms.
will have a benefit to participants currently taking prescribed antidepressants who have not
experienced complete remission of their depression symptoms.
Inclusion Criteria:
Detroit VA Patients with major depression, mild to moderate treated with an SSRI and not
having complete remission of symptoms as defined by "feeling their normal selves"
Randomized into two groups:
Experimental: will receive month supply of deplin 15mg, L-tyrosine 6g/d into 2 divided
doses, and L-tryptophan 2g/d into 2 divided doses.
Control: will receive month supply of deplin 15mg , and 2 placebo pills.
Beck Depression Scale (BDI-2) to be administered at baseline and every 2 weeks for 1 month.
Detroit VA Patients with major depression, mild to moderate treated with an SSRI and not
having complete remission of symptoms as defined by "feeling their normal selves"
Randomized into two groups:
Experimental: will receive month supply of deplin 15mg, L-tyrosine 6g/d into 2 divided
doses, and L-tryptophan 2g/d into 2 divided doses.
Control: will receive month supply of deplin 15mg , and 2 placebo pills.
Beck Depression Scale (BDI-2) to be administered at baseline and every 2 weeks for 1 month.
Inclusion Criteria:
- Veterans Administration Medical Center patients with major depression, mild to
moderate treated with an SSRI and not having complete remission of symptoms.
Exclusion Criteria:
We found this trial at
1
site
Detroit, Michigan 48201
Principal Investigator: Bella Schanzer, M.D.
Phone: 313-576-1000
Click here to add this to my saved trials
